 A total of 14 chronic HBV subjects will participate. Subjects will receive 4 single dose administrations of EYP001a during the study. There will be 2 separate dosing periods: 1 period with 2 single administrations of EYP001a in the morning, once under fasted conditions and once under fed condition separated by 48.5 hours, and 1 period with 2 single administrations of EYP001a in the evening, once under fasted conditions and once under fed condition separated by 48.5 hours. 